Introduction
In healthcare, medical professionals now strive to focus on patients’ needs and interests. The patient-centered approach is becoming more prevalent and expected to deliver quality care and ensure successful health outcomes. To deliver effective, high-quality treatment, medication optimization is crucial. Medication optimization is the process by which the medical team optimizes a patient’s prescription and ensures the patient adheres to the regimen to enhance health outcomes (Mahajan, Prabhakar, and Kapoor, 2020).
In the given situation, the main focus is on collaboration among healthcare professionals to optimize the health benefits of medicine while reducing its costs and risks (Mahajan, Prabhakar, and Kapoor, 2020). The goal of the paper is to find approaches to optimize medication use in conjunction with a 40-year-old man named Micky, who has been diagnosed with depression. Diazepam 2 mg as needed for severe anxiety and Sertraline 200 mg every morning are Micky’s doctor’s prescriptions. The patient has talked about feeling desperate and powerless, and his feelings are made worse by consuming more alcohol.
When delving deeper into the case of Micky, the paper will first focus on the benefits and side effects of each prescribed medication to identify areas of concern. Moreover, the paper will move on to a discussion of patient collaboration and considerations to enhance the individual’s health outcomes. To help reduce the impact of alcohol consumption and guide Micky in his recovery from depression, it is vital to consider patient engagement in his care by providing autonomy and considering his needs and interests.
Case Analysis
Medicine Optimization
The first area worthy of discussion is medicine optimization. The process of optimizing a patient’s medication is intricate, and several aspects related to the patient and the general practitioner (GP) can pose difficulties (Sandbæk et al., 2022). For example, general practitioners may feel obligated to follow the prescribed treatment plans for specific illnesses and anticipate patient resistance to lowering or eliminating certain prescriptions (Sandbæk et al., 2022).
Although the majority of patients state that they would be prepared to discontinue certain medications if their doctor approved, many are either unaware that they can participate in the decision-making process or reluctant to express their preferences to their doctor for medication optimization (Sandbæk et al., 2022). The reluctance stems from perceptions of insufficient assistance from the general practitioner as well as a lack of time and opportunity to discuss such demands during the session (Sandbæk et al., 2022). Thus, the patient’s interests and needs must be taken into account.
Moreover, the literature demonstrates how a proactive stance can play an immense role in treatment. Prior research has indicated that proactive patient participation is critical to optimizing medication use and removing current barriers between general practitioners and their patients (Sandbæk et al., 2022). A proposed explanation is that patient involvement produces more informed patients, who frequently make better decisions than those with less information, thereby leading to rational medicine (Sandbæk et al., 2022).
Similarly, effective chronic care is attained when a proactive, organized clinical team engages with an informed, engaged patient (Sandbæk et al., 2022). As a result, one can see the effects of medication optimization and the essential role of patient engagement. Without proper patient education and involvement, as well as collaboration among healthcare professionals, poor outcomes are likely.
Therapeutic Effects and Potential Side Effects
Moving on, it is vital to consider both the therapeutic effects and possible adverse consequences of the prescribed medications in Micky’s instance. Among the selective serotonin reuptake inhibitors (SSRIs) class of antidepressants is sertraline (Arias et al., 2021). The main mechanism of action of the antidepressant sertraline is the inhibition of presynaptic serotonin absorption (Arias et al., 2021).
For the management of anxiety-related disorders, post-traumatic stress disorder, episodes of panic, and obsessive-compulsive behaviors, sertraline is administered (Arias et al., 2021). The drug builds up due to this obstruction of serotonin reuptake (Arias et al., 2021). Because the central nervous system’s serotonin regulates emotions, character, and alertness, treating conditions like major depression can benefit from limiting serotonin reuptake (Arias et al., 2021). Therefore, the therapeutic effects of the drug involve the minimization of anxiety and depression symptoms.
Micky, however, claims that he has become worse since beginning the prescription. This could be attributed to several issues, such as the course of depression or a unique reaction to the drug. The GP has received concerns from his partner over whether the drug is “the right thing for him.”
At the same time, it must be noted that, within six weeks, sertraline reduces anxiety-related symptoms, leading to expressed improvements in psychological well-being (Lewis et al., 2019). Still, the effects of depressive symptoms are more gradual and require time to manifest (Lewis et al., 2019). In order to consider other approaches to managing depressed symptoms that may not advance, both doctors and patients ought to be conscious of the signs that are expected to improve.
Furthermore, it is crucial to consider the side effects of sertraline. Syncope, dizziness, constipation, vomiting, excessive sweating, sensitivity, disorientation, hallucinations, shaking, sleepiness, impotence, ejaculation disorder, weariness, allergies, and female sexual disorder are among the main adverse effects of sertraline (Arias et al., 2021). Sertraline may reduce platelet aggregation, which increases the risk of infection (Arias et al., 2021).
The QT interval can be somewhat prolonged by sertraline; however, this prolongation is dose-dependent (Arias et al., 2021). Moreover, sertraline can seldom cause serotonin syndrome symptoms; however, this usually occurs when it is used with another serotonergic drug (Arias et al., 2021). These symptoms include muscle stiffness, vomiting, tremors, hypersensitivity, restlessness, and hyperthermia (Arias et al., 2021). Finally, similar to other types of antidepressants, sertraline can boost the likelihood of suicidal thoughts and actions among patients who are suffering from serious depression (Arias et al., 2021). Therefore, Micky should consider that his psychological state may be affected by potential side effects.
Additionally, another medication, diazepam, should be reviewed. This drug has been approved for the treatment of anxiety disorders, for the short-term alleviation of signs of anxiety, for the treatment of particular individuals with refractory seizures, and for other seizure-related disorders (Dhaliwal, Rosani, and Saadabadi, 2023). Diazepam is prescribed for medical sedation, the management of recurring convulsive seizures, and the temporary alleviation of anxiety symptoms (Pádua-Reis et al., 2021). Similar to other benzodiazepines, diazepam induces an allosteric potentiation of GABAergic transmission and a general reduction in brain activity by increasing the attachment of natural gamma-aminobutyric acid (GABA) to its receptors (Pádua-Reis et al., 2021). Thus, the given drug can be more effective for the patient, given his persistent anxiety and depression.
Similar to the previous medication, side effects must be acknowledged. Since the drug’s introduction in the early 1960s, the adverse effects of diazepam, including dependency, lethargy, memory loss, tremors, and even car accidents, have been extensively studied (Pádua-Reis et al., 2021). Since Micky takes Diazepam regularly, there may be a risk of reliance. Additionally, he has acknowledged feeling despondent and powerless, which is made worse by an increase in his alcohol consumption. This should be discussed, and alternate methods of treating acute anxiety should be investigated.
Patient Collaboration
Furthermore, patient collaboration with Micky should be central to the provided care. Patient engagement, which happens when individuals learn to take charge of their own health and address issues with guidance and support from specialists, is essential for shared decision-making (Galletta et al., 2022). A healthcare professional who values patient autonomy and strives to improve patients’ capacity for critical thought and their ability to make independent, well-informed decisions about their own health is the first step toward patient empowerment (Galletta et al., 2022).
Research indicates that patients who actively participate in their diagnosis and treatment have better outcomes (Galletta et al., 2022). Including individuals in treatment and decision-making enhances their understanding of their options, clarifies the potential risks and benefits of the course of therapy, and enables them to make diagnostic decisions that align with their beliefs and choices (Galletta et al., 2022). In this way, patient involvement increases the patient’s involvement in the entire decision-making process. Therefore, in the case of Micky, it will be possible to give him thorough information about the drugs, including their advantages, possible drawbacks, and substitutes. It is also critical to address his doubts and uncertainties about the drug’s efficacy.
Healthcare providers can assist Micky in making decisions consistent with his values and interests by actively involving him in the decision-making process. When healthcare professionals tailor and harmonize treatment for every client and balance their general approach to care, taking into account the individual’s beliefs and preferences, the best accessible research findings, and their own clinical experience, they include patient values and interests (Tringale et al., 2022). They specifically aim for congruence by tailoring care to each patient (Tringale et al., 2022). Thus, experts modify information tailored to a patient’s requirements, values, and preferences.
Considerations
Finally, when it comes to the considerations that must be involved in Micky’s case, alcohol abuse is the primary area of focus. Drinking alcohol is strongly rooted in British culture and is typically connected to celebration, pleasure, and leisure (Madden et al., 2019). Alcohol use carries some danger for all users and is connected to ill health in several intricate ways. The management of several therapies for long-term disorders can be burdensome for patients and healthcare workers (Madden et al., 2019).
Alcohol use disorder (AUD) frequently co-occurs with psychiatric diseases, including anxiety and mood disorders (McHugh & Weiss, 2019). When both conditions coexist, there is a higher chance of suicidal thoughts and actions, as well as a worse prognosis and intensity than with each condition alone (Castillo-Carniglia et al., 2019). The co-occurrence of major depression and AUD is more common than would be predicted by chance, given the prevalence of these diseases in the general population (McHugh & Weiss, 2019). Thus, the treatment of depression in Micky’s case should be combined with the treatment of alcohol abuse.
Moreover, alcohol abuse can lead to the deterioration of drug effectiveness and decreased adherence to treatment. There is a rising concern about the possible effects of polypharmacy and poor adherence associated with treatment regimens for various conditions (Madden et al., 2019). Dependency on pharmaceutical drugs is another issue (Madden et al., 2019).
While opinions on what defines an alcohol-interactive medication vary, it is well-recognized that older persons are more susceptible to negative consequences from using medications and alcohol at the same time (Madden et al., 2019). A thorough evaluation of Micky’s alcohol consumption should be carried out together, and suitable treatments, such as counseling or a referral to specialized services, should be taken into consideration.
Conclusion
In summary, it is crucial to think about patient engagement in Micky’s care by giving him autonomy and taking into account his needs and interests to help lessen the effects of alcohol usage and assist him in his recovery from depression. Improving a patient’s medication regimen is a complex process influenced by various patient- and general practitioner–related factors that can create difficulties.
In Micky’s case, it is critical to take into account both the positive outcomes and the possible adverse reactions of the drugs that were prescribed. Sertraline is a member of the selective serotonin reuptake inhibitor class of antidepressants. The medication diazepam is authorized to treat anxiety disorders. Shared decision-making requires patient involvement, which occurs when people learn to manage their own health and address problems with the advice and assistance of experts. This means providing Micky with comprehensive information on the drugs, including their benefits, potential side effects, and alternatives.
Reference List
Arias, H. R., et al. (2021) ‘Is the antidepressant activity of selective serotonin reuptake inhibitors mediated by nicotinic acetylcholine receptors?‘, Molecules (Basel, Switzerland), 26(8).
Castillo-Carniglia, A., et al. (2019) ‘Psychiatric comorbidities in alcohol use disorder‘, The lancet. Psychiatry, 6(12), pp. 1068–1080.
Dhaliwal, J. S., Rosani, A., and Saadabadi, A. (2023) Diazepam. National Library of Medicine.
Ferraguti, F., Striessnig, J., and Huck, S. (Eds.). (2021) Cell signaling and neural circuits in chronic diseases of the central nervous system. Frontiers Media.
Gadelha Figueiredo, E., Wlling, L. C., and Nunes Rabelo, N. (Eds.). (2021) Neurocritical care for neurosurgeons: principles and applications. Springer International Publishing.
Galletta, M., et al. (2022) ‘Patient involvement in shared decision-making: do patients rate physicians and nurses differently?‘, International Journal of Environmental Research and Public Health, 19(21).
Gandhi, S. (2022) Textbook of mental health and psychiatric nursing: principles and practice. Elsevier Health Sciences.
Holland, E. J. (2022) The nurse′s guide to mental health medicines. SAGE Publications.
Huddart, R., et al. (2020) ‘PharmGKB summary: sertraline pathway, pharmacokinetics‘, Pharmacogenetics and Genomics, 30(2), pp. 26–33.
Lewis, G., et al. (2019) ‘The clinical effectiveness of sertraline in primary care and the role of depression severity and duration (PANDA): a pragmatic, double-blind, placebo-controlled randomised trial’, Psychiatry, 6(11), pp. 903–914.
Madden, M., et al. (2019) ‘Conceptualising alcohol consumption in relation to long-term health conditions: exploring risk in interviewee accounts of drinking and taking medications’, PloS One, 14(11).
Mahajan, C., Prabhakar, H., and Kapoor, I. (Eds.). (2020). Pharmacology in clinical neurosciences: A quick guide. Springer Nature Singapore.
McHugh, R. K., and Weiss, R. D. (2019) Alcohol use disorder and depressive disorders. Alcohol Research: Current Reviews, 40(1), 1-8.
NHS. (n.d.a) About diazepam.
NHS. (n.d.b) About sertraline.
Nikfarjama, Z., et al. (2022) Pharmaceutical applications of 1, 4-benzodiazepines. In Benzodiazepine-based drug discovery (pp. 125-182). Elsevier Science.
Riederer, C., et al. (Eds.). (2022) NeuroPsychopharmacotherapy. Springer International Publishing.
Sandbæk, A., et al. (2022) ‘Involving patients in medicines optimisation in general practice: a development study of the “PREparing patients for active involvement in medication review” (PREPAIR) tool’, BMC Primary Care, 23(1), 122.
Tameem, A., Collantes Celador, E., and Rudiger, J. (Eds.). (2022) Essential notes in pain medicine. OUP Oxford.
Tringale, M., et al. (2022) ‘Integrating patient values and preferences in healthcare: a systematic review of qualitative evidence’, BMJ Open, 12(11).
Appendix
Drug: Diazepam
Indication for use
Diazepam is a member of the benzodiazepine class of medications (NHS, n.d.a). It is used for the management of epilepsy or episodes, spasms of the muscles, and anxiety. Additionally, it is used in hospitals to lessen the signs of alcohol withdrawal, like perspiration and trouble sleeping (NHS, n.d.a).
Pharmacokinetics
Absorption
Peak plasma concentrations typically reach one to one and a half hours after oral diazepam treatment, when over 90% of the drug has been absorbed (Mahajan, Prabhakar, and Kapoor). When taken with food, absorption is both slowed down and delayed (Mahajan, Prabhakar, and Kapoor).
Distribution
Benzodiazepines are very lipophilic, and the medication redistributes swiftly, despite having a reasonably quick onset of effect (Ferraguti, Striessnig, and Huck, 2021). In general, 0.8 to 1.0 L/kg is the average distribution of volume (Ferraguti, Striessnig, and Huck, 2021).
Metabolism
The microsomal enzymes CYP2C19 and CYP3A4 primarily degrade diazepam into a number of active metabolites, chiefly desmethyldiazepam (Ferraguti, Striessnig, and Huck, 2021).
Excretion/Elimination
A protracted final elimination (half-life of approximately 48 hours) occurs after the first distribution (Gadelha Figueiredo, Wlling, and Nunes Rabelo, 2021). Urine is where diazepam and its derivatives are primarily eliminated (Gadelha Figueiredo, Wlling, and Nunes Rabelo, 2021).
Pharmacodynamics
Diazepam binds to particular binding locations on the α-γ subunit contacts of the receptor for GABAA, which has been shown to be a positive dynamic regulator (Nikfarjama et al., 2022). The drug’s association with these locations causes a marked increase in chloride ion inflow in the neurons, which in turn causes highly polarized postsynaptic membranes and a rise in depression in the central nervous system (Nikfarjama et al., 2022).
Counselling/Advice
It is not advised for the patient to take diazepam for more than four weeks (NHS, n.d.a). It is important to inform the patient not to consume alcohol when taking diazepam. It has the ability to induce profound sleepiness (NHS, n.d.a). Although diazepam addiction is conceivable, patients who take it for up to four weeks at the lowest dose that relieves their symptoms are less likely to develop an addiction (NHS, n.d.a).
Potential Side Effects
Common
- Sedation
- Confusion
- Fatigue
Uncommon
- Blurred vision
- Cough
- Chills
Rare
- Nausea
- Dysarthria
- Constipation (Gadelha Figueiredo, Wlling, and Nunes Rabelo, 2021).
Drug: Sertraline
Indication for Use
One class of antidepressant called a selective serotonin reuptake inhibitor (SSRI) is sertraline (NHS, n.d.b). In addition to treating depression, it is also employed on occasion to treat anxiety disorders, post-traumatic stress disorder, and obsessive-compulsive behaviors (NHS, n.d.b).
Pharmacokinetics
Absorption
Sertraline is absorbed gradually, reaching maximal concentrations 4–10 hours after intake (Huddart et al., 2021).
Distribution
Sertraline is extensively dispersed, with an estimated volume of dispersion exceeding 20 liters per kilogram. In the circulatory system, sertraline is highly protein-bound (98%) and attaches to human serum albumin with an elevated attraction through hydrogen bonding (Tameem, Collantes Celador, and Rudiger, 2021).
Metabolism
Sertraline is mostly metabolized by CYP3A4 and CYP2B6 (Tameem, Collantes Celador, and Rudiger, 2021).
Excretion/Elimination
Due to the high rate of metabolism, 12–14% of the drug’s unmodified sertraline is eliminated through the urine (Tameem, Collantes Celador, and Rudiger, 2021).
Pharmacodynamics
Sertraline increases the activity of serotonergic neurons by specifically blocking serotonin absorption (Riederer et al., 2022). This causes the CNS’s synaptic serotonin level to rise, which causes a variety of physiological alterations linked to an improvement in serotonergic neural communication (Riederer et al., 2022).
Counselling/Advice
Sertraline typically takes between four and six weeks to fully take effect, although patients should start feeling better in as little as two weeks (NHS, n.d.b). When using sertraline, patients may have fluctuations in appetite, leading to weight gain or loss (NHS, n.d.b).
Potential Side Effects
Common
- Sickness
- Pain in the head
- Having difficulty sleeping (Holland, 2022)
Uncommon
- Diarrhea
- Confusion
- Aggressive reaction (Gandhi, 2022)
Rare
- Fever
- Rapid speech
- Dehydrated oral tissues (NHS, n.d.b).